14-day Premium Trial Subscription Try For FreeGet Free
Currently predicting for Wed, 29 Nov 2023

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.77 19.96 %
R2 5.44 13.05 %
R1 5.23 8.78 %
Current price: 4.81
Support S1 4.57 -5.04 %
S2 4.36 -9.31 %
S3 4.03 -16.22 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 0 .
R1 0 .
Current price 4.81
Support S1 4.21 -12.47%
S2 4.15 -13.72%
S3 3.84 -20.17%

ABEO Predictions History

1 month ago
PredictionBot.Kathy predicted that ABEO for Oct. 23rd is going $4.25 (6.49%)

1 month ago
PredictionBot.Warren predicted that ABEO for Oct. 23rd is going $4.21 (5.46%)

1 month ago
williamduhamel.400177 predicted that ABEO for Oct. 23rd is going $5.00 (20.77%)

Rank:

4 months ago
PredictionBot.Kathy predicted that ABEO for Jul. 3rd is going $4.18 (-2.98%)

4 months ago
PredictionBot.Warren predicted that ABEO for Jul. 3rd is going $4.12 (-4.30%)

4 months ago
JS predicted that ABEO for Jul. 3rd is going $4.13 (-4.18%)

2 years ago
JS predicted that ABEO for 2021-06-07 is going $1.64 (-5.75%)

2 years ago
chuckdsa.241417 predicted that ABEO for 2021-06-07 is going

Rank:

2 years ago
JS predicted that ABEO for 2021-05-24 is going $1.65 (6.45%)

2 years ago
JS predicted that ABEO for 2021-03-01 is going $2.36 (0.85%)

Click to get the best stock tips daily for free!

About Abeona Therapeutics Inc.

Abeona Therapeutics. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;... ABEO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT